Sanofi Stunned As FDA Says No To CAD Drug Sutimlimab
Deficiencies At Third-Party Manufacturing Facility
The French major's hopes for launching its rare blood disorder drug sutimlimab soon have been scuppered by a complete response letter from the FDA after inspecting a third-party facility responsible for making the first-in-class therapy.
